Labcorp Holdings Inc. (ETR:N6B)
Germany · Delayed Price · Currency is EUR | Market Cap | 22.76B +14.3% |
| Revenue (ttm) | 12.56B +6.4% |
| Net Income | 877.31M +31.3% |
| EPS | 10.57 +33.2% |
| Shares Out | n/a |
| PE Ratio | 25.94 |
| Forward PE | 16.63 |
| Dividend | 2.47 (0.89%) |
| Ex-Dividend Date | Aug 28, 2026 |
| Volume | 2 |
| Open | 280.00 |
| Previous Close | 280.00 |
| Day's Range | 276.00 - 280.00 |
| 52-Week Range | 224.00 - 292.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Labcorp Holdings
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseas... [Read more]
Financial Performance
In 2025, Labcorp Holdings's revenue was $13.95 billion, an increase of 7.25% compared to the previous year's $13.01 billion. Earnings were $876.50 million, an increase of 17.49%.
Financial numbers in USD Financial StatementsNews
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
BURLINGTON, N.C., Sept. 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
Labcorp price target raised to $365 from $350 at Truist
Truist analyst David MacDonald raised the firm’s price target on Labcorp (LH) to $365 from $350 and keeps a Buy rating on the shares as part of a broader research…
Labcorp Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Long-term guidance through 2026 was reaffirmed, with strong revenue and EPS growth targets, margin expansion, and robust free cash flow. Specialty testing, technology investments, and acquisitions are key growth drivers, while regulatory headwinds like PAMA are actively managed. Oncology, neurology, and consumer health initiatives are highlighted as major opportunities.
Labcorp price target raised to $380 from $361 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Labcorp (LH) to $380 from $361 and keeps a Buy rating on the shares.
Labcorp price target raised to $330 from $320 at Barclays
Barclays raised the firm’s price target on Labcorp (LH) to $330 from $320 and keeps an Equal Weight rating on the shares following the investor day.
Labcorp Holdings Transcript: Investor Day 2026
The event outlined a strategy centered on specialty testing, technology-driven innovation, and global scale to drive 5%-8% revenue CAGR through 2029, with strong margin and EPS growth. Specialty areas like oncology and neurology are key growth drivers, supported by AI, digital platforms, and disciplined capital deployment.
Labcorp Holdings Slides: FY 2026
Labcorp Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 10, 2026.
Labcorp provides long-term outlook through 2029
Labcorp (LH) expects to achieve compound annual adjusted EPS growth of 8.5%-11.5% and compound annual revenue growth of 5%-8% through 2029. Sees adjusted operating margin expansion of 75-150 basis poi...
Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
Reaffirms full-year 2026 guidance Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5%...
Great Point Partners III Sells MLM Medical Labs to Labcorp
GREENWICH, Conn. and MÖNCHENGLADBACH, Germany--(BUSINESS WIRE)--Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to a...
Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.
Labcorp acquires MLM Medical Labs, terms not disclosed
Labcorp (LH) announced the acquisition of MLM Medical Labs, a global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of th...
Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials
Acquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents BURLINGTON, N.C., Sept. 8, 2026 /PRNewswire/ -- Labcorp (NYSE: LH)...
Labcorp announces enhancements to Labcorp Global Trial Connect
Labcorp (LH) announced enhancements to the digital experience of Labcorp Global Trial Connect. The redesigned platform introduces new capabilities across the Labcorp Sponsor and Labcorp Investigator p...
Labcorp launches next generation of Labcorp Global Trial Connect
Labcorp (LH) announced enhancements to the digital experience of Labcorp Global Trial Connect. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor and Labcorp Investig...
Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity
Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making BURLINGTON, N.C., Aug. 31, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of...
Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
BURLINGTON, N.C., Aug. 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team w...
Labcorp to offer Elecsys pTau-217 test for Alzheimer’s disease
Labcorp (LH) announced it will offer the Elecsys pTau-217 test following clearance by the U.S. FDA. Developed by Roche Diagnostics (RHHBY), the blood test aids in identifying amyloid pathology associa...
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings Measures phosphorylated Tau 21...
Labcorp, NACHC announce strategic alliance
Labcorp (LH) and the National Association of Community Health Centers announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health ini...
Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health Centers BURLINGTON, N.C. and BETHESDA, Md.
Labcorp to Host Investor Day on September 10, 2026
BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on T...
Labcorp price target raised to $355 from $320 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Labcorp (LH) to $355 from $320 and keeps an Outperform rating on the shares. The firm upped the company’s estimates…
Labcorp’s PGDx elio tissue complete CDx approved by FDA
Labcorp (LH) announced that the FDA has approved Labcorp’s PGDx elio tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who…
Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targete...